Program
frespaciguat
Also written as “Frespaciguat” and “[14C] MK-5475”.
Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension · COVID-19, led by Merck.
Furthest: phase 3, since Jan 27, 20216 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 61 open or running | phase 3since Jan 27, 2021 | Nov 13, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2018First study: phase 1 study in Pulmonary Arterial HypertensionFirst studyNCT03744637 · 25 enrolled · Moldova, Republic of
- Apr 29, 2020Phase 1 study in Hypertension, PulmonaryNCT04370873 · 22 enrolled · United States, Israel, Moldova, Republic of
- Jun 8, 2020Phase 1 study in COVID-19NCT04425733
- Jan 27, 2021Phase 3 study in Pulmonary Arterial HypertensionNCT04732221 · 168 enrolled · United States, Argentina, Australia and more
- Nov 3, 2022Phase 2 study in Hypertension, PulmonaryNCT05612035 · 129 enrolled · United States, Argentina, Australia and more
- Jan 10, 2025Phase 1 study in HealthyNCT06777602 · 8 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06777602Healthy · United States | 1 | Completed | Sep 30, 2022 | 8 |
| NCT05612035Hypertension, Pulmonary · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 9, 2026 | 129 |
| NCT04732221Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | Jan 4, 2024 | 168 |
| NCT04425733COVID-19 | 1 | Withdrawn | Nov 10, 2020 | 0 |
| NCT04370873Hypertension, Pulmonary · United States, Israel, Moldova, Republic of | 1 | Completed | Jan 12, 2022 | 22 |
| NCT03744637Pulmonary Arterial Hypertension · Moldova, Republic of | 1 | Completed | Dec 11, 2020 | 25 |
How it is read
Names in the registry
- “Frespaciguat”, 5 entries
- “[14C] MK-5475”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, Pulmonary, 2 studies
- Pulmonary Arterial Hypertension, 2 studies
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.